Three-Year Exclusivity Questioned By Sen. Edwards, GPHA’s Jaeger
This article was originally published in The Tan Sheet
Executive Summary
Sen. John Edwards (D-N.C.) may be interested in re-examining the three-year market exclusivity provision under Hatch/Waxman as discussion on generic drug reform moves forward on Capitol Hill
You may also be interested in...
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states